Spago Nanomedical (SPAGO) investor relations material

Industry trends and market dynamics

• Radioactive pharmaceuticals are a rapidly growing field in cancer treatment, driven by recent market successes and increased interest from major pharmaceutical companies.

• Current radiopharmaceuticals are limited to a few cancer types due to their reliance on specific molecular targets, mainly used for metastatic prostate cancer and neuroendocrine tumors.

• There is significant unmet need for broader application across more cancer types, which new technologies aim to address.

Technology and clinical development

• TumorADD uses the clinically proven isotope Lutetium-177, combined with a proprietary, stable, and non-toxic polymer carrier designed for optimal tumor targeting.

• The candidate, 177LU-SN201, is in phase 1 clinical trials, showing promising safety and biodistribution profiles across multiple solid tumor types.

• Preclinical and early clinical data indicate effective tumor uptake and minimal toxicity, especially to sensitive organs like the kidneys.

Clinical trial progress and results

• The ongoing phase 1 trial in Australia has enrolled 12 patients across 10 cancer types, with no dose-limiting toxicities observed so far.

• Safety profile is consistent and manageable, with reversible, asymptomatic blood changes and no significant kidney toxicity.

• Imaging and pharmacokinetic data align with expectations, and dose escalation is planned to reach clinically relevant levels.